HighPoint Advisor Group’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $690K | Sell |
11,379
-52,678
| -82% | -$3.07M | 0.03% | 361 |
|
|
2025
Q4 | $3.46M | Buy |
64,057
+13,183
| +26% | +$634K | 0.08% | 224 |
|
|
2025
Q3 | $2.29M | Sell |
50,874
-2,600
| -5% | -$121K | 0.11% | 146 |
|
|
2025
Q2 | $2.48M | Sell |
53,474
-4,692
| -8% | -$230K | 0.13% | 133 |
|
|
2025
Q1 | $2.86M | Sell |
58,166
-2,761
| -5% | -$161K | 0.17% | 108 |
|
|
2024
Q4 | $3.41M | Buy |
60,927
+4,160
| +7% | +$232K | 0.19% | 95 |
|
|
2024
Q3 | $2.94M | Sell |
56,767
-2,756
| -5% | -$129K | 0.17% | 104 |
|
|
2024
Q2 | $2.92M | Buy |
59,523
+7,348
| +14% | +$329K | 0.17% | 105 |
|
|
2024
Q1 | $2.35M | Sell |
52,175
-376
| -0.7% | -$19.2K | 0.17% | 107 |
|
|
2023
Q4 | $2.75M | Buy |
+52,551
| New | +$2.76M | 0.2% | 93 |
|
|
2022
Q2 | $5.41M | Buy |
+70,944
| New | +$5.4M | 0.59% | 33 |
|
|
2021
Q3 | $3.56M | Buy |
60,192
+1,361
| +2% | +$89.6K | 0.35% | 59 |
|
|
2021
Q2 | $3.93M | Buy |
58,831
+10,495
| +22% | +$684K | 0.4% | 55 |
|
|
2021
Q1 | $3.03M | Buy |
48,336
+1,540
| +3% | +$95.8K | 0.35% | 61 |
|
|
2020
Q4 | $2.8M | Buy |
46,796
+2,135
| +5% | +$131K | 0.34% | 65 |
|
|
2020
Q3 | $2.85M | Buy |
44,661
+11,125
| +33% | +$670K | 0.52% | 43 |
|
|
2020
Q2 | $1.99M | Buy |
33,536
+685
| +2% | +$41K | 0.43% | 55 |
|
|
2020
Q1 | $2.04M | Buy |
32,851
+1,030
| +3% | +$63K | 0.49% | 50 |
|
|
2019
Q4 | $2.14M | Buy |
31,821
+9,684
| +44% | +$555K | 0.44% | 56 |
|
|
2019
Q3 | $1.28M | Buy |
22,137
+1,822
| +9% | +$85.6K | 0.28% | 72 |
|
|
2019
Q2 | $868K | Buy |
20,315
+168
| +0.8% | +$7.83K | 0.2% | 93 |
|
|
2019
Q1 | $951K | Buy |
20,147
+658
| +3% | +$32.8K | 0.23% | 88 |
|
|
2018
Q4 | $1M | Buy |
19,489
+1,541
| +9% | +$82.8K | 0.26% | 86 |
|
|
2018
Q3 | $913K | Buy |
17,948
+95
| +0.5% | +$5.64K | 0.25% | 94 |
|
|
2018
Q2 | $1.09M | Sell |
17,853
-2,948
| -14% | -$159K | 0.29% | 86 |
|
|
2018
Q1 | $1.11M | Buy |
20,801
+1,438
| +7% | +$92.5K | 0.3% | 84 |
|
|
2017
Q4 | $1.24M | Buy |
19,363
+343
| +2% | +$21.5K | 0.35% | 70 |
|
|
2017
Q3 | $1.18M | Buy |
19,020
+469
| +3% | +$27.4K | 0.37% | 63 |
|
|
2017
Q2 | $1.04M | Hold |
18,551
| – | – | 0.33% | 73 |
|
|
2017
Q1 | $1.04M | Sell |
18,551
-8,491
| -31% | -$466K | 0.33% | 73 |
|
|
2016
Q4 | $1.54M | Buy |
27,042
+9,989
| +59% | +$546K | 0.5% | 47 |
|
|
2016
Q3 | $967K | Sell |
17,053
-4,606
| -21% | -$296K | 0.34% | 72 |
|
|
2016
Q2 | $1.33M | Buy |
21,659
+8,372
| +63% | +$592K | 0.47% | 52 |
|
|
2016
Q1 | $939K | Buy |
13,287
+560
| +4% | +$35.3K | 0.57% | 45 |
|
|
2015
Q4 | $819K | Buy |
12,727
+7,728
| +155% | +$511K | 0.54% | 54 |
|
|
2015
Q3 | $296K | Buy |
+4,999
| New | +$317K | 0.33% | 106 |
|
Other funds holding BMY
VCM
VPM
HighPoint Advisor Group's BMY Position: Q1 2026 in Review
HighPoint Advisor Group reduced its Bristol-Myers Squibb (BMY) stake by 82% in Q1 2026, selling an estimated $3.07M and leaving 11,379 shares worth $690K. The position accounts for 0.03% of the portfolio, ranked #361.
HighPoint Advisor Group first reported a position in BMY in Q3 2015 and has held it in 36 quarters since. The position peaked at $5.41M in Q2 2022. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- HighPoint Advisor Group held 11,379 shares of Bristol-Myers Squibb worth $690K as of Q1 2026.
- HighPoint Advisor Group sold 52,678 Bristol-Myers Squibb shares in Q1 2026, an estimated $3.07M.
- Bristol-Myers Squibb made up 0.03% of HighPoint Advisor Group's portfolio in Q1 2026, its #361 holding.
- HighPoint Advisor Group first reported a position in Bristol-Myers Squibb in Q3 2015 and has held it in 36 quarters since.
- HighPoint Advisor Group's Bristol-Myers Squibb position peaked at $5.41M in Q2 2022.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on HighPoint Advisor Group's 13F filing for Q1 2026, filed 14 May 2026.